• Conference Proceeding

Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients aged over 75 Years undergoing total hip or knee arthroplasty

Citation

Wolowacz, S., Roskell, N., Plumb, J., Clemens, A., Robinson, P., Dolan, G., & Brenkel, I. (2009). Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients aged over 75 Years undergoing total hip or knee arthroplasty. In [12], pp. A151–A151. .

Abstract